Digest Network Come funziona
Network
/
Società
Ma
Non verificato

MaaT Pharma

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

34 comunicati stampa

Guarda tutti i comunicati
05/11/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Oncologia
Industria
MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
04/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Eventi
Fiere
Mercato azionario
MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Oncologia
Eventi
Industria
MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
07/10/2025
Biologia
Biotecnologia
Salute
Sanità
Farmaceutica
Oncologia
Scienza
Medicina - Varie
Industria
MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
17/09/2025
Salute
Oncologia
Medicina - Varie
Sanità
Mercato azionario
Mercato del lavoro
Eventi
Industria
Pubblico Esercizio/Vendita al dettaglio
MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
28/07/2025
Oncologia
Salute
Biologia
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
02/07/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Web e Social Network
Mercato del lavoro
Telefonia e Varie
Industria
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
19/06/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Eventi
Industria
Web e Social Network
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
13/06/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Eventi
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0
02/06/2025
Scienza
Biologia
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
Fonte
MaaT Pharma
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0